Literature DB >> 16435172

False-positive results in neonatal screening for cystic fibrosis based on a three-stage protocol (IRT/DNA/IRT): Should we adjust IRT cut-off to ethnic origin?

D Cheillan1, M Vercherat, F Chevalier-Porst, M Charcosset, M O Rolland, C Dorche.   

Abstract

Since 1979, newborn screening for cystic fibrosis (CF) has been possible by measuring immunoreactive tryspinogen (IRT) in blood spots. In France, a programme based on a three-stage strategy (IRT/DNA/IRT) started in 2002. In the Rhône-Alpes area, the positive screening rate (i.e. the proportion of samples sent for genotyping) observed after the first IRT measurement was higher than the expected rate (0.65% versus 0.50%), without a greater CF incidence. We hypothesized that the IRT reference range could differ according to the ethnic origin of the newborns. 35 141 newborns were studied and divided into two groups: European ethnic group 26 324 (75%) and North African ethnic group 8817 (25%). 243 positive newborns were identified: 146 (60%) in the European ethnic group and 97 (40%) in the North African ethnic group. Three CF patients and 11 unaffected heterozygotes were found in the European group, but no mutations were found in the North African group. Mean IRT values and the percentage of IRT values over the cut-off were significantly higher in the North African group than in the European group (mean IRT = 21.17 microg/L and 19.74 microg/L, p < 0.0001; %IRT > cut-off = 1.1% and 0.5%, respectively). For the positive screened newborns, term and IRT mean were comparable, whereas birth weight was higher in the North African ethnic group. These results lead us to conclude that (i) newborns from families of North African origin have higher IRT values and (ii) most of the positive screened newborns in this population could be considered as 'false positives'. These conclusions could explain, in part, the large variations seen in the positive screening rate in the French CF neonatal screening and raise the question whether it is relevant to adapt cut-off to ethnic origin of the newborns.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16435172     DOI: 10.1007/s10545-005-0067-0

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  17 in total

1.  Neonatal screening for cystic fibrosis in Brittany, France: assessment of 10 years' experience and impact on prenatal diagnosis.

Authors:  V Scotet; M de Braekeleer; M Roussey; G Rault; P Parent; M Dagorne; H Journel; A Lemoigne; J P Codet; M Catheline; V David; A Chaventré; I Duguépéroux; C Verlingue; I Quéré; B Mercier; M P Audrézet; C Férec
Journal:  Lancet       Date:  2000-09-02       Impact factor: 79.321

2.  Ethnic variations in birthweight percentiles in Kuwait.

Authors:  M M Alshimmiri; M S Hammoud; E A Al-Saleh; K M S Alsaeid
Journal:  Paediatr Perinat Epidemiol       Date:  2003-10       Impact factor: 3.980

3.  Prevalence of CFTR mutations in hypertrypsinaemia detected through neonatal screening for cystic fibrosis.

Authors:  V Scotet; M De Braekeleer; M P Audrézet; L Lodé; C Verlingue; I Quéré; B Mercier; I Duguépéroux; J P Codet; M P Moineau; P Parent; C Férec
Journal:  Clin Genet       Date:  2001-01       Impact factor: 4.438

4.  Non-specific elevation of immunoreactive trypsinogen in sick infants.

Authors:  D Ravine; R I Francis; D M Danks
Journal:  Eur J Pediatr       Date:  1993-04       Impact factor: 3.183

5.  Dried-blood spot screening for cystic fibrosis in the newborn.

Authors:  J R Crossley; R B Elliott; P A Smith
Journal:  Lancet       Date:  1979-03-03       Impact factor: 79.321

6.  Racial differences in birth weight of term infants in a northern California population.

Authors:  Ashima Madan; Sharon Holland; John E Humbert; William E Benitz
Journal:  J Perinatol       Date:  2002 Apr-May       Impact factor: 2.521

7.  Significant ethnic variation in total and free testosterone concentration.

Authors:  Adrian H Heald; Fiona Ivison; Simon G Anderson; Kennedy Cruickshank; Ian Laing; J Martin Gibson
Journal:  Clin Endocrinol (Oxf)       Date:  2003-03       Impact factor: 3.478

8.  Neonatal screening for cystic fibrosis: France rises to the challenge.

Authors:  J P Farriaux; M Vidailhet; M L Briard; V Belot; J L Dhondt
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

9.  Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population.

Authors:  C Corbetta; M Seia; A Bassotti; A Ambrosioni; A Giunta; R Padoan
Journal:  J Med Screen       Date:  2002       Impact factor: 2.136

10.  C-reactive protein as a screening test for cardiovascular risk in a multiethnic population.

Authors:  Sonia S Anand; Fahad Razak; Qilong Yi; Bonnie Davis; Ruby Jacobs; Vlad Vuksan; Eva Lonn; Koon Teo; Matthew McQueen; Salim Yusuf
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-06-17       Impact factor: 8.311

View more
  4 in total

1.  Extra corporeal membrane oxygenation (ECMO) therapy in a 3-year-old child with cystic fibrosis: a tale of hope.

Authors:  Patrick Stafler; Colin Wallis
Journal:  J R Soc Med       Date:  2009-07       Impact factor: 5.344

Review 2.  Newborn screening for cystic fibrosis: a lesson in public health disparities.

Authors:  Lainie Friedman Ross
Journal:  J Pediatr       Date:  2008-09       Impact factor: 4.406

3.  Differences in immunoreactive trypsin values between type of feeding and ethnicity in neonatal cystic fibrosis screening: a cross-sectional study.

Authors:  Ernesto Cortés; Ana María Roldán; Antonio Palazón-Bru; María Mercedes Rizo-Baeza; Herminia Manero; Vicente Francisco Gil-Guillén
Journal:  Orphanet J Rare Dis       Date:  2014-11-07       Impact factor: 4.123

4.  Ethnic variability in newborn metabolic screening markers associated with false-positive outcomes.

Authors:  Gang Peng; Yishuo Tang; Neeru Gandotra; Gregory M Enns; Tina M Cowan; Hongyu Zhao; Curt Scharfe
Journal:  J Inherit Metab Dis       Date:  2020-04-17       Impact factor: 4.982

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.